| Description |
1 online resource |
| Contents |
Intro -- Torsades de Pointes -- Copyright -- Dedication -- Contents -- Contributors -- Preface -- Chapter 1: Overview of torsades de pointes -- Introduction -- Definitions and descriptions of TdP -- Defining TdP -- ECG characteristics of TdP -- Historical perspectives -- Evolving understanding on mechanisms of TdP -- Pathophysiology of TdP -- Genesis of TdP -- Perpetuation of TdP -- Spotlight on: Canine models of TdP -- Overview of LQTS and TdP -- Relationship between LQTS and TdP -- Introduction to inherited and acquired QT interval prolongation -- Inherited QT interval prolongation |
|
Acquired QT interval prolongation -- Interplay of inherited and acquired factors in LQTS -- Epidemiology of TdP -- Overall rates of prolonged QTc interval and TdP -- Inherited LQTS and TdP -- Inherited LQTS -- Inherited TdP -- Acquired LQTS and TdP -- Acquired LQTS -- Acquired TdP -- Consequences of LQTS and TdP -- Symptoms of LQTS and TdP -- Spotlight on: Treatment of inherited LQTS -- Prognosis -- Prognosis in patients with inherited LQTS -- Prognosis in patients with acquired LQTS -- Future directions -- References -- Chapter 2: Torsades de pointes associated with inherited channelopathies |
|
Introduction -- Long QT syndrome -- Acquired LQTS and the link to congenital LQTS -- Torsades de pointes arrhythmias -- Therapeutic options for torsades de pointes -- Short-coupled torsades de pointes arrhythmia -- Therapeutic options for short-coupled torsades de pointes -- Conclusions -- References -- Chapter 3: Drug-induced torsades de pointes -- Introduction -- Medications as a cause of TdP -- Drug-induced QT interval prolongation and prediction of TdP risk -- Determining causality for drug-induced QT interval prolongation and TdP: The adverse drug event causality analysis (ADECA) .. |
|
Evidence requirements for risk categories -- Scientific validation of the QTdrugs list and the ADECA process -- Frequency of prescription of QT interval-prolonging medications -- Epidemiology of TdP and death associated with QT interval-prolonging drugs -- Management of risk of drug-induced QT prolongation and TdP -- Conclusion -- References -- Chapter 4: Mechanisms of torsades de pointes -- Introduction -- A brief introduction to ventricular action potential electrogenesis, including INa, IKs, and IKr -- Drugs linked to torsades de pointes in humans and the association with IKr/hERG block |
|
A role for pharmacological activation of late sodium current in diLQTS -- IKs and repolarization reserve -- Cellular arrhythmogenic events resulting from action potential prolongation: Early afterdepolarizations -- How is torsades de pointes initiated and maintained? -- Insights from genetically altered animal models of LQTS -- Insights into mechanisms of torsades de pointes from models used to study drug-induced long QT syndrome -- Constructing an integrated mechanistic description of torsades de pointes: Is there a final necessary mechanism? |
| Notes |
Print version record |
| Subject |
Arrhythmia.
|
|
Arrhythmia -- Chemotherapy
|
|
Arrhythmias, Cardiac
|
|
Arrhythmia
|
|
Arrhythmia -- Chemotherapy
|
| Form |
Electronic book
|
| Author |
Tisdale, James E., editor.
|
| ISBN |
9780128214619 |
|
0128214619 |
|
